Strategic Partnership Enhances Market Reach
Cardiac Biotech Solutions, Inc. (OTCID: CBSC), a trusted name in non-invasive cardiac monitoring products, recently announced an exciting new agreement with Noventis Medical. This exclusive five-year distribution agreement empowers CBSC to extend its innovative products into key Latin American markets, namely Costa Rica, Panama, Colombia, and Argentina.
Details of the Agreement
The agreement stipulates a commitment by Noventis Medical to a substantial contract value of $600,000 USD. Notably, Noventis will also have a right of first refusal for future distribution opportunities throughout other Central and South American nations, provided they can match competing offers. This provision not only strengthens their current partnership but also positions both companies for future growth.
CEO Insights on Market Expansion
Charles Martin, the Chief Executive Officer of CBSC, expressed optimism about this strategic collaboration. He stated, “We are delighted to expand our international presence through this new strategic partnership with Noventis Medical.” Martin believes that this partnership will bolster their market position and lay solid groundwork for further expansion in the region. By establishing a foothold in these key markets, CBSC is well-poised for potential growth opportunities in the future.
Importance of Cardiac Solutions in Latin America
As cardiovascular disease remains a leading cause of mortality in the region, the importance of reliable cardiac monitoring solutions cannot be overstated. John Quam, President of Noventis Medical, emphasized the critical nature of their collaboration. He commented, “Noventis Medical is very excited to collaborate with CBSC and its product, MyCardia AT, to bring a reliable solution for identifying heart issues in the Latin American market.” The MyCardia AT device is designed to assist medical professionals in diagnosing heart conditions early, which is vital for improving patient outcomes.
Innovative Technology for Healthier Lives
The MyCardia AT event monitoring platform integrates advanced technology with user-friendly wearable devices, allowing seamless connectivity through AWS Cloud and mobile applications compatible with both iOS and Android systems. This comprehensive approach not only enhances patient compliance but also allows physicians to access more accurate health data. With successful regulatory approvals in the U.S. and ongoing submissions in Canada and China, CBSC is making significant strides toward global market saturation.
Commitment to Continuous Improvement
As the Company continues to innovate and adapt, it promises to keep shareholders and the public informed of any new developments and milestones reached. Future announcements will be made promptly through press releases and regulatory filings, ensuring transparency and fostering trust within the investment community.
About Cardiac Biotech Solutions, Inc.
Cardiac Biotech Solutions, Inc. specializes in providing cutting-edge products and services in the non-invasive cardiac monitoring sector. Through its international subsidiaries, the Company offers advanced electrocardiogram (EKG) devices and cloud-based acquisition software, aimed at improving patient compliance for individuals at risk of heart rhythm disturbances. Their mobile applications further allow users to monitor their health effectively.
Company Contact Information
Telephone: (888) 225-0870
Investor Inquiries: investor@cardiacbiotech.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter.
Frequently Asked Questions
What is the agreement between CBSC and Noventis Medical?
The agreement grants CBSC exclusive rights to distribute its products in several Latin American countries for five years.
Why is the partnership significant for CBSC?
This partnership expands CBSC's market reach and enhances its presence in key regions where cardiac issues are prevalent.
What product is being highlighted in this agreement?
The MyCardia AT event monitoring platform is central to this partnership, aiming to provide innovative solutions for heart monitoring.
How does the MyCardia AT platform benefit patients?
The platform allows for early identification of heart problems, which can lead to better health outcomes for patients.
How can investors stay informed about CBSC’s developments?
CBSC commits to regular updates through press releases and regulatory announcements to keep investors and the public informed about their progress.
